Comparing Cimerli vs Lucentis
| Cimerli (ranibizumab) | Lucentis (ranibizumab) |
|
|---|
| Cimerli (ranibizumab) | Lucentis (ranibizumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Macular Edema Following Retinal Vein Occlusion, Macular Degeneration, Myopic Choroidal Neovascularization, Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy. Cimerli may also... View more |
Prescription only
Prescribed for Macular Edema Following Retinal Vein Occlusion, Macular Degeneration, Myopic Choroidal Neovascularization, Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy. Lucentis may... View more |
Related suggestions Macular Degeneration
Diabetic Macular Edema
Macular Edema
Diabetic Retinopathy
|
|||||||||||||||
| More about Cimerli (ranibizumab) | More about Lucentis (ranibizumab) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Be the first to share your experience with this drug. |
Lucentis has an average rating of 6.1 out of 10 from a total of 15 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 27% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Cimerli side effects |
View all Lucentis side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Cimerli prices |
View all Lucentis prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Other ranibizumab brands include: Byooviz, Lucentis, Susvimo | Other ranibizumab brands include: Byooviz, Cimerli, Susvimo | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
216 hours |
216 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 1 drugs are known to interact with Cimerli:
|
A total of 1 drugs are known to interact with Lucentis:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.